Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier

BACKGROUND: Currently, high doses of cytarabine arabinoside (Ara-C)-based combined chemotherapy are commonly used in acute myeloid leukemia (AML) therapy, but severe adverse effects and poor suppression effects in leukemia cells limit the clinical therapeutic efficiency of Ara-C-based chemotherapy d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xinzhou, Jiao, Zhouguang, Zhang, Junying, Li, Feng, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088114/
https://www.ncbi.nlm.nih.gov/pubmed/37041636
http://dx.doi.org/10.1186/s12951-023-01881-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088114/
https://www.ncbi.nlm.nih.gov/pubmed/37041636
http://dx.doi.org/10.1186/s12951-023-01881-8

Ejemplares similares